Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series.
Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series.
复制标题
DOI：
10.1093/oncolo/oyad184
复制
发表时间：
2023-09-07
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
多线全身治疗失败的转移性黑色素瘤患者的管理仍然是一个重大挑战。关于抗PD-1和替莫唑胺或其他化疗药物联合治疗黑色素瘤的文献有限。在这里，我们介绍了一系列3例转移性黑色素瘤患者，以及他们在几种局部/区域治疗，联合免疫检查点抑制剂和/或靶向治疗进展后对nivolumab和替莫唑胺联合治疗的反应。新的组合策略导致所有3名患者在开始治疗后不久出现显著反应，肿瘤缓解和症状改善。第一例患者在开始治疗后15个月仍有持续反应，尽管此后他因不耐受而停用替莫唑胺。其余2例患者在4个月后显示持续缓解，耐受性良好。该病例系列表明，nivolumab和替莫唑胺可能是标准治疗难治性晚期黑色素瘤的一种有希望的选择，并需要在更大的系列中进行进一步研究。考虑到多线全身治疗后疾病进展的患者的治疗选择有限，新型组合策略的前景越来越好。该病例系列表明，nivolumab和替莫唑胺可能是标准治疗难治性晚期黑色素瘤的一种有希望的选择，需要在更大的系列中进行进一步研究。
The management of metastatic melanoma patients that fail multiple lines of systemic therapy remains a significant challenge. There is limited literature regarding combination of anti-PD-1 and temozolomide, or of other chemotherapy agents, in melanoma. Here, we present a series of 3 patients with metastatic melanoma and their responses to nivolumab and temozolomide combination therapy after progression on several local/regional therapies, combination immune checkpoint inhibitors, and/or targeted therapies. The novel combinatory strategy led to remarkable responses in all 3 patients shortly after initiating treatment with tumor remission and symptomatic improvement. The first patient has had ongoing response 15 months after initiating treatment, although he has since discontinued temozolomide due to intolerance. The remaining 2 patients show ongoing response after 4 months, with good tolerability. This case series suggests that nivolumab and temozolomide may be a promising option in the setting of advanced melanoma refractory to standard treatments, and warrants further investigation in larger series. Given the limited therapeutic options for patients who have disease progression after multiple lines of systemic therapy, there is growing promise in novel combinatorial strategies. This case series suggests that nivolumab and temozolomide may be a promising option in the setting of advanced melanoma refractory to standard treatments and warrants further investigation in larger series.
登录
查看更多内容
影响因子：
--
作者：
Hu T;Sun W;Xu Y;Qu X;Jin Y;Luo Z;Chen Y
通讯作者：
Chen Y
影响因子：
2.2
作者：
Vera Aguilera, Jesus;Paludo, Jonas;Yan, Yiyi
通讯作者：
Yan, Yiyi
影响因子：
158.5
作者：
Schmid, P.;Adams, S.;Emens, L. A.
通讯作者：
Emens, L. A.
影响因子：
45.3
作者：
Middleton, MR;Grob, JJ;Thatcher, N
通讯作者：
Thatcher, N
DOI：
10.1016/j.lungcan.2018.08.019
发表时间：
2018-11
期刊：
Lung cancer (Amsterdam, Netherlands)
影响因子：
--
作者：
Gadgeel SM;Stevenson JP;Langer CJ;Gandhi L;Borghaei H;Patnaik A;Villaruz LC;Gubens M;Hauke R;Yang JC;Sequist LV;Bachman R;Saraf S;Raftopoulos H;Papadimitrakopoulou V
通讯作者：
Papadimitrakopoulou V